Open Access

Functional capacity of reconstituted blood in 1:1:1 versus 3:1:1 ratios: A thrombelastometry study

  • Arne Driessen1, 2,
  • Nadine Schäfer1,
  • Ursula Bauerfeind3,
  • Sigune Kaske2,
  • Carolin Fromm-Dornieden1,
  • Ewa K Stuermer1 and
  • Marc Maegele2Email author
Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine201523:2

https://doi.org/10.1186/s13049-014-0080-0

Received: 9 September 2014

Accepted: 16 December 2014

Published: 9 January 2015

Abstract

Introduction

Different transfusion ratio concepts of packed red blood cells (pRBCs), fresh frozen plasma (FFP) and platelets (PLTs) have been implemented in trauma care, but the optimal ratios are still discussed. In this study the hemostatic potential of two predefined ratios was assessed by using an in vitro thrombelastometric approach. Furthermore, age effects of reconstituted blood were analyzed.

Methods

Whole blood (WB) of voluntary donors was separated into pRBCs, FFP and PLTs and reconstituted into the ratios 1:1:1 and 3:1:1 at day 1, 4, 14, and 24. Standard blood count, electrolytes and coagulation proteins were quantified. The functional coagulation in ratio- and age-specific groups was evaluated using rotational thromboelastometry (ROTEM).

Results

Several coagulation factors reduced significantly in the 3:1:1 ratio and were consistent with increased INR, decelerated clot formation times and A10 (amplitude 10 minutes after clotting time (CT)), flattened α-angle during the EXTEM and diminished MCF for distinct time points during the INTEM, FIBTEM and APTEM assays. With rising age of pRBCs the pH, sodium and potassium reached non-physiological levels.

Conclusion

Under standardized in vitro conditions the higher amount of pRBCs in the 3:1:1 ratio diluted coagulation factors significantly on the expense of its functional coagulation capacity as revealed by ROTEM results. Thus, the coagulation functionality of the 1:1:1 ratio predominated.

Keywords

Transfusion practices Acute bleeding injury Coagulopathy Thrombelastometry in trauma Ratio of components

Introduction

As there is less doubt about the components to be administered during transfusion the evidence for an appropriate transfusion ratio is still lacking [1]. Different ratios of pRBCs, FFP and PLTs are applied in clinical practice [2-4] at which the 1:1:1 ratio has been adopted by trauma centers worldwide for the acute treatment of bleeding trauma patients [5,6]. For massive transfusion the use of a RBC:FFP ratio of 1:1 or 2:1 was recommended based on systematic reviews [7-11] and a reduction of death risk for trauma patients was associated when transfused in the range of 1:1 to 2.5:1. Currently, the PROPPR study as a phase III prospective randomized trial was conducted by several trauma centers in the United States that targets the efficacy of the transfusion ratio 1:1:1 compared to 2:1:1 (pRBCs:FFP:PLTs) within a massive transfusion (MT). Overall limited evidence due to retrospective or unfinished prospective designs [12] and numerous potential confounders [1,10,13-16] as well as poor compliance to MT protocols (MTP) during resuscitation limits the expressiveness and results of these studies.

Besides transfusion ratios the application of blood products stored less than two weeks (fresh blood) or more than 14 days (old blood) is also crucially discussed. Previously, lower postoperative complications and increased long-term survival were observed after cardiac surgery when transfusing fresh compared to older blood [17,18]. A higher mortality rate and severity of transfusion related acute lung injury (TRALI) was shown after administering stored pRBC in different animal studies [18,19] with comparable results in additional studies [20-24]. Furthermore the erythrocyte cell membrane deformability irreversibly decreased with storage duration and might be responsible for reduced oxygen transport [24-29].

The present study addressed the question of a predominance of the ratios 1:1:1 and 3:1:1 of pRBCs, FFP and PLTs in contrast to whole blood on the one hand and age-specificities of fresh and old blood on the other. For this purpose, they were compared in vitro under standardized conditions by measuring electrolytes, blood and coagulation proteins as well as analyzing functionality of coagulation and at distinct time points.

Methods

Blood donation and further processing

After institutional review board approval and written informed consent a volume of 450 ml type A blood of six voluntary donors was collected in standard bags supplemented with 63 ml of CPD (citrate, phosphate, dextrose) stabilization solution. Initially, the blood was stored for 20 hours at validated CompoCool plates (Fresenius Kabi, Bad Homburg, Germany) prior to leukocyte-depletion (by filtering) and separation (by centrifugation) into pRBCs, FFP and PLTs. The pRBC of 260 ± 50 ml volume contained 100 ml of SAG-M (adenine, glucose and mannitol) solution and were stored at 4°C ± 2°C until usage. FFP was portioned in 250 ± 30 ml bags, shock-frozen and stored at −30°C. Due to the short storage life a maximum four days old PLTs bag of 260 ± 40 ml was used that had been incubated under constant agitation at 22°C ± 2°C.

Since the volume of the blood product bags differed, the pRBCs, FFPs and PLTs were weighted first before calculating its percentage of volume prior reconstitution which allowed a realistic transfusion procedure of the ratios 1:1:1 and 3:1:1 to a final volume of 50 ml. All measurements were performed at day one, four, 14, and 24. Additionally, whole blood was measured at day one. The detailed proceeding was represented in Figure 1.
Figure 1

Procedure of blood separation and reconstitution as well as subsequent experiments.

Measurement of blood parameters

All measurements were performed at the Institute of Transfusion Medicine, Cologne-Merheim Medical Centre. The standard hemogram (Full Blood Count, FBC) parameters erythrocytes, leucocytes, platelets, hemoglobin, hematocrit, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), and red blood cell distribution width (RDW) were measured on the Cell-Dyn 1700 Hematology Analyzer (Abbott Laboratories, Abbott Park, USA). International normalized ratio (INR), partial thromboplastin time (PTT), fibrinogen, antithrombin, the factors II, V, VII, VIII, IX, X, XI, XII, and VIII, protein C, protein S, d-dimer, vonWillebrand factor activity (vWF:a), and vonWillebrand factor Antigen (vWF:Ag) were quantified following the manufacturer’s manuals (Instrumentation Laboratory Company; Bedford, USA; Siemens Healthcare Diagnostics Products GmbH, Marburg, Germany) by using the ACL TOP system (Instrumentation Laboratory Company; Bedford, USA) and the APACT 4S Plus (Rolf Greiner BioChemica, Flacht, Germany).

The values of sodium, potassium, calcium, and the pH were determined by blood gas analysis via the IRMA TruPoint Blood Analysis System (Keller Medical GmbH, Bad Soden, Germany).

ROTEM® analysis

Kinetics of hemostasis was followed by ROTEM delta analysis in accordance to the manufacturer’s instructions (Tem International GmbH, Munich, Germany) (Figure 2). The 30 minutes thromboelastometric measurement included the extrinsically activated assay with tissue factor (EXTEM), the intrinsically activated test using ellagic acid (INTEM), the extrinsically activated test with tissue factor and the platelet inhibitor cytochalasin D (FIBTEM) as well as the extrinsically activated assay after blocking hyperfibrinolysis by aprotinin (APTEM). The parameters clotting time (CT), clot formation time (CFT), α-angle, amplitude 10 minutes after CT (A10), and maximal clot firmness (MCF) were analyzed for the EXTEM, INTEM and APTEM assays while the CFT was not determined for FIBTEM.
Figure 2

Kinetics of hemostasis as demonstrated by a viscoelastic test (ROTEM, Tem Innovations GmbH).

Statistics

Collected data were analyzed by the nonparametric Kruskal-Wallis test to assess the effects of time and ratio in the different time-by-ratio groups using the IBM SPSS Statistics, version 21.0 (Armonk, NY, USA). P values were corrected in the subsequent pairwise comparison of groups. Differences were considered statistically significant at p < 0.05.

The cumulative comparison of coagulation factor activity was performed by calculating the overall mean of all factors for the WB, 1:1:1 and 3:1:1 group, respectively.

Results

Blood count and electrolytes

Irrespective of blood product age, several measured parameters differed between the ratios 1:1:1 and 3:1:1 (Table 1). The quantity of erythrocytes was significantly lower in the 1:1:1 group compared to WB. Platelets were elevated in the 1:1:1 ratio at all points in time and differed significantly from the corresponding levels of the whole blood. Leucocyte depletion of the original blood samples resulted in a drastically decline in both ratios (<500/μl). While hemoglobin and hematocrit levels of the 3:1:1 ratio and the WB were likewise, the 1:1:1 ratio had significantly reduced levels in comparison with both groups at the reviewed time points. Overall, age-specific differences were not observed for erythrocytes, platelets, hemoglobin, and hematocrit. Similarly, MCV, MCH and RDW remained constant and were not affected by age or ratio.
Table 1

Significant ratio-specific differences of the ratios 1:1:1 and 3:1:1

Parameter

Day 1

Day 4

Day 14

Day 24

WB

1:1:1

3:1:1

1:1:1

3:1:1

1:1:1

3:1:1

1:1:1

3:1:1

Erythrocytes [×106/μl]

3.79 ± 0.29

2.14 ± 0.54+

3.65 ± 0.85

2.01 ± 0.14*

3.68 ± 0.29

1.96 ± 0.13*

3.3 ± 0.34

2.09 ± 0.64*

3.08 ± 0.61

Leukocytes [×103/μl]

6.55 ± 2.05

0.25 ± 0.05+

0.33 ± 0.1+

0.37 ± 0.08

0.33 ± 0.14

0.35 ± 0.1

0.25 ± 0.08

0.45 ± 0.1

0.5 ± 0.18

Platelets [×103/μl]

236.5 ± 43.1

348.5 ± 36.39+,*

226.5 ± 28.51

327.5 ± 22.42*

181 ± 44.09

359.17 ± 20.68*

231.5 ± 38.83

334.83 ± 37.5*

231.5 ± 58.11

Hemoglobin [g/dl]

11.78 ± 1.11

6.6 ± 1.67+,*

11.43 ± 2.54

6.2 ± 0.56*

11.42 ± 1.08

6.12 ± 0.5*

10.38 ± 1.25

6.47 ± 2.27*

9.76 ± 1.71

Hematocrit [%]

37.08 ± 3.21

20.85 ± 4.29+,*

35.7 ± 7.14

20.27 ± 1.55*

37.13 ± 3.19

19.5 ± 1.76*

32.97 ± 3.88

21.33 ± 7.26

30.92 ± 5.29

MCHC [g/dl]

31.75 ± 0.7

31.47 ± 1.27

31.9 ± 0.65

30.57 ± 0.6

30.72 ± 0.5

30.75 ± 0.18*

31.5 ± 0.64

30.25 ± 0.49

30.83 ± 0.7

pH

6.92 ± 0.06

7.04 ± 0.04+

6.95 ± 0.05

7.03 ± 0.05*

6.9 ± 0.04

6.91 ± 0.08*

6.76 ± 0.03

6.89 ± 0.03*

6.69 ± 0.06

Sodium [mM]

139.67 ± 2.33

142.62 ± 6.15

145.37 ± 5.14

140.48 ± 1.63*

142.3 ± 0.89

138.67 ± 0.81

138.43 ± 2.09

137.42 ± 0.99

136.72 ± 1.67

Potassium [mM]

3.33 ± 0.4

3.12 ± 0.38

2.83 ± 0.78

3.91 ± 0.38*

4.69 ± 0.35

6.72 ± 1.3*

9.19 ± 0.95

7.45 ± 0.48*

13.01 ± 0.15

EXTEM CFT [s]

101.83 ± 49.17

59.83 ± 10.94*

125.33 ± 27.5

54.83 ± 5.49*

127.67 ± 50.71

59.33 ± 16.46*

139.5 ± 46.87

74.33 ± 27.98

99.5 ± 34.81

INTEM CFT [s]

133.5 ± 67.16

70.33 ± 24.83

144.17 ± 99.03

55.5 ± 6.8*

119.5 ± 39.51

114.17 ± 94.2

166.5 ± 78.58

67 ± 34.48

92.5 ± 18.17

APTEM CFT [s]

119.17 ± 74.34

72.67 ± 22.81

108 ± 33.89

70.5 ± 16.88*

131.33 ± 57.6

66.83 ± 19.06*

133.5 ± 44.28

65.33 ± 30.74

84.33 ± 19.31

INR

1.12 ± 0.1

1.03 ± 0.05*

1.23 ± 0.08

1.13 ± 0.05*

1.52 ± 0.25

1.12 ± 0.04*

1.53 ± 0.15

1.17 ± 0.08*

1.45 ± 0.14

PTT [s]

38.33 ± 4.59

33.67 ± 3.83

36.83 ± 5.49

33.83 ± 2.79*

44.83 ± 6.88

38.5 ± 4.14*

47.67 ± 7.15

36.83 ± 4.4*

43.5 ± 5.32

Fibrinogen [mg/dl]

254.17 ± 51.33

226.83 ± 23.79

173.8 ± 31.3+

224.33 ± 21.94*

147.33 ± 30.74

215.17 ± 25.56*

143.67 ± 16.46

240.17 ± 20.47*

170 ± 17.12

Antithrombin [%]

77.17 ± 7.41

68.83 ± 7.78

49.17 ± 8.54+

64.67 ± 3.98*

38.17 ± 7.25

67.17 ± 3.31*

38.33 ± 6.12

63.17 ± 3.43*

41.33 ± 3.27

Factor II [%]

82.33 ± 8.33

76.33 ± 4.23

55.17 ± 7.19+

74 ± 5.48*

46.33 ± 8.71

68.5 ± 8.07*

43.83 ± 9.7

63.17 ± 5.34

45.67 ± 5.54

Factor V [%]

81.17 ± 7.41

72.67 ± 6.89

53 ± 10.1+

57.33 ± 4.41*

34.5 ± 6.25

58.67 ± 3.72*

35.83 ± 2.64

56.33 ± 6.98*

40.33 ± 5.09

Factor VII [%]

73.67 ± 11.33

79.83 ± 10.46*

56.33 ± 7.76

67.17 ± 9.15*

42 ± 9.27

64.67 ± 9.67*

41.33 ± 8.31

61.17 ± 11.41*

45 ± 9.92

Factor VIII [%]

95.33 ± 29.12

83.75 ± 13.35

57.83 ± 10.8+

71.8 ± 9.88*

46.17 ± 16.55

53.83 ± 11.2*

39.17 ± 8.8

71.67 ± 30.94

53.33 ± 23.89

Factor IX [%]

89 ± 8.2

95 ± 5.22*

70.67 ± 8.62

87 ± 5.33*

54.5 ± 10.56

74.5 ± 10.91*

51.17 ± 11.36

77.33 ± 16.37*

50.67 ± 9.14

Factor X [%]

73.5 ± 9.09

79.33 ± 5.92*

54.17 ± 5.88

72.33 ± 8.24*

48.83 ± 6.68

68.67 ± 13.98*

44.17 ± 11.07

71.17 ± 10.82*

49.83 ± 10.38

Factor XI [%]

83.8 ± 29.8

96 ± 15.3*

71.67 ± 6.35

91.83 ± 18.8

72.83 ± 33.88

72.67 ± 15.07*

49.5 ± 12.32

66.5 ± 11.78*

48.17 ± 8.33

Factor XII activity [%]

86.17 ± 28.27

75.67 ± 9.14*

54.67 ± 8.26+

88 ± 10.1*

48.33 ± 13.85

76.5 ± 22.73*

50.17 ± 20.44

69.67 ± 16.01*

48.33 ± 9.42

Factor XIII [%]

115.67 ± 11.18

100.67 ± 12.4

77.17 ± 10.67+

97.5 ± 11.71*

67.17 ± 16.04

86.33 ± 6.38*

65.5 ± 4.09

92.17 ± 19.05*

61 ± 1.79

Protein C activity [%]

71.67 ± 13.98

70.33 ± 5.96*

50.5 ± 4.97+

70.67 ± 7.42*

41.33 ± 8.36

60.67 ± 6.74*

37.33 ± 7.26

63.67 ± 5.16*

48.17 ± 6.97

Protein S activity [%]

89.17 ± 16.93

60.33 ± 7.12

43.17 ± 11.41+

33 ± 4.34*

21.17 ± 8.82

55 ± 8.12*

33.33 ± 7.39

43.8 ± 15.42

28.83 ± 12.24

v. Willebr. activation [%]

128.83 ± 39.78

97 ± 19.01

72.2 ± 15.9+

98.67 ± 18.35*

67.17 ± 23.04

67.5 ± 26.61

46 ± 14.56

82.33 ± 28.11

60.17 ± 22.11

v. Willebr. antigen [%]

141.83 ± 45.28

112.67 ± 27.81

77.2 ± 17.08+

114.83 ± 27.69*

71.67 ± 22.17

78 ± 25.87

53.17 ± 17.68

107.83 ± 39.91

76.5 ± 28.74

Values are represented as mean ± standard deviation. Differences (p < 0.05) are marked as + when comparing with whole blood (WB) and as *to compare both ratios irrespective of time point.

Only few age effects could be observed (Table 2) and thereof most notably the values of potassium and sodium. Independent of ratio potassium increased progressively over time being 2.4- and 4.6-fold higher after 24 days in the 1:1:1 and 3:1:1 ratio, respectively. In contrast, sodium reduced with increasing age and differed significantly in both ratios between day one and 24. The environment of the reconstituted blood slightly acidified as in both ratios the pH value decreased with age and was reduced stronger in the 3:1:1 group from day four (Table 2). No alteration of calcium was determined during the measurement.
Table 2

Significant age-specific differences at day one, four, 14, and 24

Parameter

1:1:1

3:1:1

Day 1

Day 4

Day 14

Day 24

Day 1

Day 4

Day 14

Day 24

Leukocytes [×103/μl]

0.25 ± 0.05c

0.37 ± 0.08

0.35 ± 0.1

0.45 ± 0.1

0.33 ± 0.1

0.33 ± 0.14

0.25 ± 0.08

0.5 ± 0.18

pH

7.04 ± 0.04b,c

7.03 ± 0.05e

6.91 ± 0.08

6.89 ± 0.03

6.95 ± 0.05b,c

6.9 ± 0.04e

6.76 ± 0.03

6.69 ± 0.06

Sodium [mM]

142.62 ± 6.15c

140.48 ± 1.63e

138.67 ± 0.81

137.42 ± 0.99

145.37 ± 5.14b,c

142.3 ± 0.89e

138.43 ± 2.09

136.72 ± 1.67

Potassium [mM]

3.12 ± 0.38b,c

3.91 ± 0.38e

6.72 ± 1.3

7.45 ± 0.48

2.83 ± 0.78b,c

4.69 ± 0.35e

9.19 ± 0.95

13.01 ± 0.15

INTEM CT [s]

204.83 ± 13.6c

229.33 ± 28.51

243.5 ± 121.51

284.33 ± 67.57

206.83 ± 16.46

200.83 ± 14.93e

245 ± 84.52

259.83 ± 25.86

FIBTEM CT [s]

57.83 ± 10.65

108.33 ± 91.24

69.5 ± 38.9

46.17 ± 29.17

84.33 ± 15.72c

52.33 ± 26.24

132.33 ± 107.69

45.17 ± 19.09

INR

1.03 ± 0.05c

1.13 ± 0.05

1.12 ± 0.04

1.17 ± 0.08

1.23 ± 0.08 b

1.52 ± 0.25

1.53 ± 0.15

1.45 ± 0.14

Factor II [%]

76.33 ± 4.23c

74 ± 5.48

68.5 ± 8.07

63.17 ± 5.34

55.17 ± 7.19

46.33 ± 8.71

43.83 ± 9.7

45.67 ± 5.54

Factor V [%]

72.67 ± 6.89a,c

57.33 ± 4.41

58.67 ± 3.72

56.33 ± 6.98

53 ± 10.1a,b

34.5 ± 6.25

35.83 ± 2.64

40.33 ± 5.09

Factor VII [%]

79.83 ± 10.46c

67.17 ± 9.15

64.67 ± 9.67

61.17 ± 11.41

56.33 ± 7.76

42 ± 9.27

41.33 ± 8.31

45 ± 9.92

Factor IX [%]

95 ± 5.22b

87 ± 5.33

74.5 ± 10.91

77.3 ± 16.37

70.67 ± 8.62c

54.5 ± 10.56

51.17 ± 11.36

50.67 ± 9.14

Factor XI [%]

96 ± 15.3

91.83 ± 18.8

72.67 ± 15.07

66.5 ± 11.78

71.67 ± 6.35b,c

72.83 ± 33.88

49.5 ± 12.32

48.17 ± 8.33

Factor XIII [%]

100.67 ± 12.4

97.5 ± 11.71

86.33 ± 6.38

92.17 ± 19.05

77.17 ± 10.67c

67.17 ± 16.04

65.5 ± 4.09

61 ± 1.79

Protein C activity [%]

70.33 ± 5.96

70.67 ± 7.42

60.67 ± 6.74

63.67 ± 5.16

50.5 ± 4.97b

41.33 ± 8.36

37.33 ± 7.26

48.17 ± 6.97

Protein S activity [%]

60.33 ± 7.12b

33 ± 4.34

55 ± 8.12

43.83 ± 15.42

43.17 ± 11.41a

21.17 ± 8.82

33.33 ± 7.39

28.83 ± 12.24

D-dimer [μg/l]

216.6 ± 48.43b

239.5 ± 43.98d

123 ± 26.78

156 ± 50.45

185.2 ± 36.64

180.67 ± 37.6

119.5 ± 17.04

150.5 ± 32.44

Values are represented as mean ± standard deviation. Lowercases indicate significant differences (p < 0.05) between: a - day 1 and 4, b - day 1 and 14, c - day 1 and 24, d - day 4 and 14, e - day 4 and 24, and f - day 14 and 24, respectively.

Coagulation proteins

For almost all coagulation factors ratio-specific reductions in the 3:1:1 group were observed at any time point when comparing both ratios (Table 1). The factors VII, IX, X and XII were constantly and significantly reduced in 3:1:1 samples, independent of age while the factors II, V, and XIII significantly declined not before day four. Similar to the blood count parameter the quantity of coagulation factors was affected minor by age (Table 2). Although several factors tended to be reduced after 24 days only the factors II, V and VII measured in the 1:1:1 ratio and factors IX, XI and XIII in the 3:1:1 group reached the level of significance. The cumulative factors were comparable in the WB and 1:1:1 group whereas a precise decline was observed when comparing both groups to the 3:1:1 ratio at day 1 or when comparing the 1:1:1 with the 3:1:1 ratio at the respective time points (Figure 3).
Figure 3

Quantitative cumulative factor quantity (summing up coagulation factors FII, FV, FVII, FVIII, F IX, FX, FXI, FXII, FXIII) and INR of the WB, 1:1:1 and 3:1:1 groups. Levels are represented as mean and standard deviation. Bars are depicted as dotted (WB), light grey (1:1:1) and dark grey (3:1:1). Significances were observed at *p < 0.05; **p < 0.01; ***p < 0.001.

The activity of the coagulation inhibitors antithrombin and protein C as well as its cofactor protein S were significantly lowered in the 3:1:1 compared to WB (day one) and in most cases considerably reduced in 1:1:1 ratio at all ages (Table 2). Fibrinogen was also diluted in 3:1:1 samples from day four on (Table 1).

Functionality of coagulation

Consistent with the reduction of coagulation proteins in the 3:1:1 ratio an elevated PTT and INR were observed in the 1:1:1 group irrespective of age. Both values reached significant levels with the exception of PTT at day one (Table 1). Furthermore, the INR trended to increase with age in both ratios. A declined functionality of the extrinsic and intrinsic system was also measured by ROTEM analysis. The CFT significantly decelerated at almost all time points in the 3:1:1 group of the EXTEM approach (Table 1). Similarly, CTs were prolonged by trend in the 3:1:1 group, however, not reaching significant level. Also the α-angle and the clot amplitudes after 10 and 30 minutes declined in the 3:1:1 ratio at day one, four and 14 (Figure 4).
Figure 4

Functional characterization of coagulation via ROTEM analysis. The α-angle, amplitude after 10 minutes (A10) and maximum clot firmness (MCF) after 30 minutes of the EXTEM, INTEM, FIBTEM, and APTEM assays are represented as mean and standard deviation. Bars are depicted as dotted (WB), light grey (1:1:1) and dark grey (3:1:1). Significances were observed at *p < 0.05; **p < 0.01; ***p < 0.001. Age differences (p < 0.05) were indicated with the lowercases a (day 1 ↔ 4), b (day 1 ↔ 14), c (day 1 ↔ 24), d (day 4 ↔ 14), e (day 4 ↔ 24), and f (day 14 ↔ 24), respectively.

For the INTEM, FIBTEM and APTEM assays the main difference were observed after four and 14 days (Table 1, Figure 4). Thereafter mostly tendencies were determined due to a high variation within the groups. However, the MCF seemed to be the most consistent value in these three approaches providing significant declines in the 3:1:1 ratio irrespective of the activation pathway. As observed for other measured values the age differences were inconsistent and being present for few comparisons of EXTEM α-angle as well as for INTEM and FIBTEM CTs (Table 2).

Discussion

The ratio concept

Over 10 years ago the correlation of transfusion practices and patients’ outcome was stronger focused in trauma research. Several publications [2,10,11,30] underlined the superiority for using defined ratios of pRBCs and FFPs solely or combined with PLTs. Due to heterogeneity such as patients’ inclusion criteria (if they were even defined) and in the applied ratios (1:1; 2:1, 3:1 etc.) the evidence of these studies was limited. In 2007, Borgman et al. [2] firstly presented a systematic analysis of trauma care including a transfusion ratio concept that increased the survival rate in major bleeding patients. This study still represents the unproven guideline in handling these kinds of seriously injured patients. Currently, the multicenter PROPPR study systematically compared the transfusion ratios 1:1:1 and 2:1:1 (pRBCs:FFP:PLTs) in a clinical trial and brought first (but final) evidence in the discussion regarding transfusion ratios [31].

In this in vitro study the physiological characteristics of the 3:1:1 ratio go along with a reduction of all coagulation factors resulting in a lowered hemostasiological potential that was indicated by elevated INR and viscoelastic tests. The thrombelastometric findings (ROTEM) in dilution effects in the 3:1:1 ratio became evident by a decreased dynamic clot formation and clot quality as indicated by a flattened α-angle and a lowered clot firmness after 10 and 30 minutes (A10, MCF). Furthermore, a trend of decelerated clot formation could be observed.

There was no evidence that the processing of plasma (freezing, storage, thawing) may explain the changes in factor quantity and viscoelastic functionality of the 3:1:1 group, since 10 days of storage and subsequent thawing did not affect coagulation factors as shown previously [32]. In addition, this proceeding effect would have been observed in the 1:1:1 ratio as well. To ensure the allocation of functional factors in FFPs and to further minimize influencing effects on coagulation, maximum 4 days old factor-rich plasma was used at any time point before reconstitution. Thus, the lower quantity of coagulation factors whether significantly reduced in the 3:1:1 ratio or trend to be decreased can rather be explained by diluting effects than by inactivation of factors. Furthermore, cumulative factors were comparable between WB and 1:1:1 providing an adequate initial basis for coagulation [30,33]. In summary the hemostasiological potential of the 1:1:1 ratio rather referred to that of WB. Transfusion ratios leading to a nearly physiological hemostasiological potential and an effective coagulation may reduce the amount of pRBCs being transfused. According to the current European guideline [34] transfusion of pRBC is recommended in patients with Hb values below 7 mg/dl.

The findings of the present study were in line with results of a recently published in vitro study in which a dilution effect in a 3:1 (pRBC:FFP) ratio was determined by simulating postpartum hemodilutional coagulopathy [35]. Therefore, there seemed to be a superiority of the 1:1 ratio of pRBC and FFP transfusion optimized by an additional application of the same ratio of PLTs. Interestingly, no dilution effect due to FFP was observed though not only concentrates of clotting factors were used. Similar results were reported for a thrombelastography (TEG) approach in which different ratios of pRBC:FFP:PTL were analyzed in vitro. In line with the results of the present study, a higher proportion of pRBCs such as 8:4:1 of pRBC:FFP:PTLs resulted in decreased abilities to form a stable clot (reduced angle and maximal amplitude) [36].

This in vitro experiment enabled the assessment of quantitative and functional coagulation under standardized environments and revealed main findings in dilution and associated effects on functional coagulation. However, interrelated physiological impact on TIC like hypothermia, acidosis, inflammation, shock or the preliminary treatments such as pre-hospital volume administration [37-39] and therefore, dilution and hyperpermeability, shedding of the endothelial glycocalyx with autoheparinization [40] and activation of the protein C pathway [41,42] influence its coagulation potency. Disease pattern leading to major bleeding are very individual. Therefore, we could only propose a possible influence of the applied ratio of blood products in human. Efficient therapy of coagulopathy reduces significantly morbidity and mortality in trauma patients [2,43]. Independent from (surgical) therapies, coagulopathy is recognized as independent disease with an individual need for therapy nowadays [44,45].

Age of blood products

Addressing the question if there are differences in newer compared to older blood trends of reduced corpuscular components after 24 days were shown. Inverse the highest potassium and lowest pH value were measured at day 24 which might be explained by an increasing erythrocytes degradation [46]. With regard to clinical practice one should consider that potassium levels higher than 8 mmol/l have to be taken into further account when applying the 3:1:1 ratio. As demonstrated in previous clinical studies [27-29,47,48] in which the length of storage of pRBC influenced hemolysis, changes in deformability as well as osmotic fragility the results of this study did not reveal any continuous age effect according to the hemostasiological potential. However, the changes of potassium (13.01 ± 0.15 mM), sodium (136.72 ± 1.67 mM) and pH levels (6.69 ± 0.06) associated with aging blood products cannot be disregarded when applying to patients after 24 days of storage.

Regarding clotting time and clot formation a continuous but not significant increase was detected for INTEM while FIBTEM values reacted vice versa.

Conclusions

This systematic in vitro study offers valuable information about transfusion ratios as well as influencing age effects on coagulation. With regard to limitations of in vitro trials, the presented results suggest a superiority of 1:1:1 ratio in a physiological setting in case of transfusion encouraging higher use of plasma rather than pRBCs. Thus, dosage, ratio and administration of blood components still remain a dichotomy between benefits and harms whereby this study highlighted the need for multi-center clinical trials to determine the optimal transfusion strategy.

Key messages

  • The higher proportion of pRBCs of the 3:1:1 ratio resulted in dilution properties of almost all coagulation factors and inhibitors.

  • Dilution likewise affected the hemostasiological potential which was indicated by an elevated PTT and INR in the 3:1:1 compared to 1:1:1 group.

  • The reduced functional coagulation of the 3:1:1 ratio was further specified by a decelerated CFT, flattened α-angle and diminished MCF of the ROTEM analysis.

Notes

Abbreviations

ACT: 

Activated clotting time

APTT: 

Activated partial thromboplastin time

BGA: 

Blood gas analysis

CFT: 

Clot formation time

Functional fibrinogen: 

Tissue factor–activated thromboelastography including a platelet inhibitor

FBC: 

Full blood count

FFP: 

Fresh frozen plasma

INR: 

International normalized ratio

MA: 

Maximum amplitude

MCF: 

Maximum clot firmness

MTP(s): 

Massive transfusion protocol(s)

PLT(s): 

Platelet concentrate(s)

pRBCs: 

packed red blood cells

TEG: 

Thromboelastography

WB: 

Whole blood

Declarations

Acknowledgement

We kindly thank M. Lassonczyk and A. Camphausen for technical support.

Authors’ Affiliations

(1)
Institute for Research in Operative Medicine, Faculty of Health, Department of Medicine, Witten/Herdecke University
(2)
Department of Traumatology, Orthopaedic Surgery and Sports Traumatology, Cologne-Merheim Medical Centre (CMMC), Witten/Herdecke University, Campus Cologne-Merheim
(3)
Institute of Transfusion Medicine Cologne-Merheim Medical Centre (CMMC), Witten/Herdecke University, Campus Cologne-Merheim, Cologne (Germany)

References

  1. Curry N, Stanworth S, Hopewell S, Dorée C, Brohi K, Hyde C. Trauma-induced coagulopathy--a review of the systematic reviews: is there sufficient evidence to guide clinical transfusion practice? Transfus Med Rev. 2011;25:217–31. e2.PubMedView ArticleGoogle Scholar
  2. Borgman MA, Spinella PC, Perkins JG, Grathwohl KW, Repine T, Beekley AC, et al. The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital. J Trauma. 2007;63:805–13.PubMedView ArticleGoogle Scholar
  3. Gunter OL, Au BK, Isbell JM, Mowery NT, Young PP, Cotton BA. Optimizing outcomes in damage control resuscitation: identifying blood product ratios associated with improved survival. J Trauma. 2008;65:527–34.PubMedView ArticleGoogle Scholar
  4. Hoyt DB, Dutton RP, Hauser CJ, Hess JR, Holcomb JB, Kluger Y, et al. Management of coagulopathy in the patients with multiple injuries: results from an international survey of clinical practice. J Trauma. 2008;65:755–64. discussion 764–5.PubMedView ArticleGoogle Scholar
  5. Young PP, Cotton BA, Goodnough LT. Massive transfusion protocols for patients with substantial hemorrhage. Transfus Med Rev. 2011;25:293–303.PubMed CentralPubMedView ArticleGoogle Scholar
  6. Levi M, Fries D, Gombotz H, van der Linden P, Nascimento B, Callum JL, et al. Prevention and treatment of coagulopathy in patients receiving massive transfusions. Vox Sang. 2011;101:154–74.PubMedView ArticleGoogle Scholar
  7. Lier H, Krep H, Schroeder S, Stuber F. Preconditions of hemostasis in trauma: a review. The influence of acidosis, hypocalcemia, anemia, and hypothermia on functional hemostasis in trauma. J Trauma. 2008;65:951–60.PubMedView ArticleGoogle Scholar
  8. Cushing M, Shaz BH. Blood transfusion in trauma patients: unresolved questions. Minerva Anestesiol. 2011;77:349–59.PubMedGoogle Scholar
  9. Stahel PF, Moore EE, Schreier SL, Flierl MA, Kashuk JL. Transfusion strategies in postinjury coagulopathy. Curr Opin Anaesthesiol. 2009;22:289–98.PubMedView ArticleGoogle Scholar
  10. Johansson PI, Stensballe J. Hemostatic resuscitation for massive bleeding: the paradigm of plasma and platelets–a review of the current literature. Transfusion. 2010;50:701–10.PubMedView ArticleGoogle Scholar
  11. Phan HH, Wisner DH. Should we increase the ratio of plasma/platelets to red blood cells in massive transfusion: what is the evidence? Vox Sang. 2010;98(3 Pt 2):395–402.PubMedView ArticleGoogle Scholar
  12. Maegele M, Lefering R, Paffrath T, Tjardes T, Simanski C, Bouillon B. Red-blood-cell to plasma ratios transfused during massive transfusion are associated with mortality in severe multiple injury: a retrospective analysis from the Trauma Registry of the Deutsche Gesellschaft für Unfallchirurgie. Vox Sang. 2008;95:112–9.PubMedView ArticleGoogle Scholar
  13. Kozek-Langenecker S, Sørensen B, Hess JR, Spahn DR. Clinical effectiveness of fresh frozen plasma compared with fibrinogen concentrate: a systematic review. Crit Care. 2011;15:R239.PubMed CentralPubMedView ArticleGoogle Scholar
  14. Lier H, Böttiger BW, Hinkelbein J, Krep H, Bernhard M. Coagulation management in multiple trauma: a systematic review. Intensive Care Med. 2011;37:572–82.PubMedView ArticleGoogle Scholar
  15. Rajasekhar A, Gowing R, Zarychanski R, Arnold DM, Lim W, Crowther MA, et al. Survival of trauma patients after massive red blood cell transfusion using a high or low red blood cell to plasma transfusion ratio. Crit Care Med. 2011;39:1507–13.PubMedView ArticleGoogle Scholar
  16. Murad MH, Stubbs JR, Gandhi MJ, Wang AT, Paul A, Erwin PJ, et al. The effect of plasma transfusion on morbidity and mortality: a systematic review and meta-analysis. Transfusion. 2010;50:1370–83.PubMedView ArticleGoogle Scholar
  17. Koch CG, Li L, Sessler DI, Figueroa P, Hoeltge GA, Mihaljevic T, et al. Duration of red-cell storage and complications after cardiac surgery. N Engl J Med. 2008;358:1229–39.PubMedView ArticleGoogle Scholar
  18. Tung J-P, Fraser JF, Nataatmadja M, Colebourne KI, Barnett AG, Glenister KM, et al. Age of blood and recipient factors determine the severity of transfusion-related acute lung injury (TRALI). Crit Care. 2012;16:R19.PubMed CentralPubMedView ArticleGoogle Scholar
  19. Solomon SB, Wang D, Sun J, Kanias T, Feng J, Helms CC, et al. Mortality increases after massive exchange transfusion with older stored blood in canines with experimental pneumonia. Blood. 2013;121:1663–72.PubMed CentralPubMedView ArticleGoogle Scholar
  20. Inaba K, Branco BC, Rhee P, Blackbourne LH, Holcomb JB, Spinella PC, et al. Impact of the duration of platelet storage in critically ill trauma patients. J Trauma. 2011;71:1766–73. discussion 1773–4.PubMedView ArticleGoogle Scholar
  21. Spinella PC, Carroll CL, Staff I, Gross R, Mc Quay J, Keibel L, et al. Duration of red blood cell storage is associated with increased incidence of deep vein thrombosis and in hospital mortality in patients with traumatic injuries. Crit Care. 2009;13:R151.PubMed CentralPubMedView ArticleGoogle Scholar
  22. Weinberg JA, McGwin G, Griffin RL, Huynh VQ, Cherry SA, Marques MB, et al. Age of transfused blood: an independent predictor of mortality despite universal leukoreduction. J Trauma. 2008;65:279–82. discussion 282–4.PubMedView ArticleGoogle Scholar
  23. Wang D, Sun J, Solomon SB, Klein HG, Natanson C. Transfusion of older stored blood and risk of death: a meta-analysis. Transfusion. 2012;52:1184–95.PubMedView ArticleGoogle Scholar
  24. Leal-Noval SR, Muñoz-Gómez M, Arellano-Orden V, Marín-Caballos A, Amaya-Villar R, Marín A, et al. Impact of age of transfused blood on cerebral oxygenation in male patients with severe traumatic brain injury. Crit Care Med. 2008;36:1290–6.PubMedView ArticleGoogle Scholar
  25. Frank SM, Abazyan B, Ono M, Hogue CW, Cohen DB, Berkowitz DE, et al. Decreased erythrocyte deformability after transfusion and the effects of erythrocyte storage duration. Anesth Analg. 2013;116:975–81.PubMed CentralPubMedView ArticleGoogle Scholar
  26. Tinmouth A, Chin-Yee I. The clinical consequences of the red cell storage lesion. Transfus Med Rev. 2001;15:91–107.PubMedView ArticleGoogle Scholar
  27. Simak J, Gelderman MP. Cell membrane microparticles in blood and blood products: potentially pathogenic agents and diagnostic markers. Transfus Med Rev. 2006;20:1–26.PubMedView ArticleGoogle Scholar
  28. Holovati JL, Wong KA, Webster JM, Acker JP. The effects of cryopreservation on red blood cell microvesiculation, phosphatidylserine externalization, and CD47 expression. Transfusion. 2008;48:1658–68.PubMedView ArticleGoogle Scholar
  29. Almizraq R, Tchir JDR, Holovati JL, Acker JP. Storage of red blood cells affects membrane composition, microvesiculation, and in vitro quality. Transfusion. 2013;53:2258–67.PubMedGoogle Scholar
  30. Gonzalez EA, Moore FA, Holcomb JB, Miller CC, Kozar RA, Todd SR, et al. Fresh frozen plasma should be given earlier to patients requiring massive transfusion. J Trauma. 2007;62:112–9.PubMedView ArticleGoogle Scholar
  31. Baraniuk S, Tilley BC, del Junco DJ, Fox EE, van Belle G, Wade CE, et al. Pragmatic Randomized Optimal Platelet and Plasma Ratios (PROPPR) Trial: Design, rationale and implementation. Injury. 2014;45:1287–95.PubMedView ArticleGoogle Scholar
  32. Tholpady A, Monson J, Radovancevic R, Klein K, Bracey A. Analysis of prolonged storage on coagulation Factor (F)V, FVII, and FVIII in thawed plasma: is it time to extend the expiration date beyond 5 days? Transfusion. 2013;53:645–50.PubMedView ArticleGoogle Scholar
  33. Armand R, Hess JR. Treating coagulopathy in trauma patients. Transfus Med Rev. 2003;17:223–31.PubMedView ArticleGoogle Scholar
  34. Spahn DR, Bouillon B, Cerny V, Coats TJ, Duranteau J, Fernández-Mondéjar E, et al. Management of bleeding and coagulopathy following major trauma: an updated European guideline. Crit Care. 2013;17:R76.PubMed CentralPubMedView ArticleGoogle Scholar
  35. Farber MK, Sadana N, Kaufman RM, Liu X, Kodali BS. Transfusion ratios for postpartum hemodilutional coagulopathy: an in vitro thromboelastographic model. Am J Obstet Gynecol. 2014;210:323. e1–7.PubMedGoogle Scholar
  36. Agren A, Edgren G, Kardell M, Ostlund A, Wikman AT. In vitro combinations of red blood cell, plasma and platelet components evaluated by thromboelastography. Blood Transfus. 2014;12:491–6.PubMed CentralPubMedGoogle Scholar
  37. Wafaisade A, Wutzler S, Lefering R, Tjardes T, Banerjee M, Paffrath T, et al. MMTR of D: Drivers of acute coagulopathy after severe trauma: a multivariate analysis of 1987 patients. Emerg Med J. 2010;27:934–9.PubMedView ArticleGoogle Scholar
  38. Meng ZH, Wolberg AS, Monroe DM, Hoffman M. The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. J Trauma. 2003;55:886–91.PubMedView ArticleGoogle Scholar
  39. Engström M, Schött U, Romner B, Reinstrup P. Acidosis impairs the coagulation: A thromboelastographic study. J Trauma. 2006;61:624–8.PubMedView ArticleGoogle Scholar
  40. Ostrowski SR, Johansson PI. Endothelial glycocalyx degradation induces endogenous heparinization in patients with severe injury and early traumatic coagulopathy. J Trauma Acute Care Surg. 2012;73:60–6.PubMedView ArticleGoogle Scholar
  41. Brohi K, Cohen MJ, Ganter MT, Matthay MA, Mackersie RC, Pittet J-F. Acute traumatic coagulopathy: initiated by hypoperfusion: modulated through the protein C pathway? Ann Surg. 2007;245:812–8.PubMed CentralPubMedView ArticleGoogle Scholar
  42. Brohi K, Cohen MJ, Davenport RA. Acute coagulopathy of trauma: mechanism, identification and effect. Curr Opin Crit Care. 2007;13:680–5.PubMedView ArticleGoogle Scholar
  43. Hess JR. Resuscitation of trauma-induced coagulopathy. Hematology Am Soc Hematol Educ Program. 2013;2013:664–7.PubMedView ArticleGoogle Scholar
  44. Cohen MJ. Acute traumatic coagulopathy: Clinical characterization and mechanistic investigation. Thromb Res. 2014;133(Suppl):S25–7.PubMedView ArticleGoogle Scholar
  45. Maegele M, Schöchl H, Cohen MJ. An update on the coagulopathy of trauma. Shock. 2014;41 Suppl 1:21–5.PubMedView ArticleGoogle Scholar
  46. Ozment CP, Mamo LB, Campbell ML, Lokhnygina Y, Ghio AJ, Turi JL. Transfusion-related biologic effects and free hemoglobin, heme, and iron. Transfusion. 2013;53:732–40.PubMedView ArticleGoogle Scholar
  47. Sambasivan CN, Kunio NR, Nair PV, Zink KA, Michalek JE, Holcomb JB, et al. High ratios of plasma and platelets to packed red blood cells do not affect mortality in nonmassively transfused patients. J Trauma. 2011;71(2 Suppl 3):S329–36.PubMedView ArticleGoogle Scholar
  48. Tinmouth A, Fergusson D, Yee IC, Hébert PC. Clinical consequences of red cell storage in the critically ill. Transfusion. 2006;46:2014–27.PubMedView ArticleGoogle Scholar

Copyright

© Driessen et al.; licensee BioMed Central. 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement